Innate Pharma S.A. (IPHA)

Innate Pharma Revenue

In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.

• Revenue (ttm): 20.12M EUR
• Revenue Growth: -67.36%
• P/S Ratio: 8.37
• Revenue / Employee: 111,166 EUR
• Employees: 181
• Market Cap: 174.32M USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	20.12M	-41.52M	-67.36%
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.